INS and breast carcinoma: In a trial of 32 women (4 dropout) with early stage breast cancer and fasting insulin of ≥45 pmol/L and glucose <7.0 mmol/L, administration of metformin 1500 mg per day for 6 months was associated with a 22.4% decrease in serum insulin [p = 0.024; (34)].